Publication | Closed Access

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab

Ras SignatureMedicinePharmacologyTreatment ResponseColorectal CancerPathologyPredictive ValueCancer TreatmentOncologyRadiation OncologyTumor MicroenvironmentCancer Research